{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:04:00Z","timestamp":1793084640089,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T00:00:00Z","timestamp":1572912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The sepsis-induced immunodepression contributes to impaired clinical outcomes of various stress conditions. This syndrome is well documented and characterized by attenuated function of innate and adaptive immune cells. Several pharmacological interventions aimed to restore the immune response are emerging of which interferon-gamma (IFN\u03b3) is one. It is of paramount relevance to obtain clinical information on optimal timing of the IFN\u03b3-treatment, \u2212tolerance, \u2212effectiveness and outcome before performing a RCT. We describe the effects of IFN\u03b3 in a cohort of 18 adult and 2 pediatric sepsis patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this open-label prospective multi-center case-series, IFN\u03b3 treatment was initiated in patients selected on clinical and immunological criteria early (&lt;\u20094\u2009days) or late (&gt;\u20097\u2009days) following the onset of sepsis. The data collected in 18 adults and 2 liver transplanted pediatric patients were: clinical scores, monocyte expression of HLA-DR (flow cytometry), lymphocyte immune-phenotyping (flow cytometry), IL-6 and IL-10 plasma levels (ELISA), bacterial cultures, disease severity, and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In 15 out of 18 patients IFN\u03b3 treatment was associated with an increase of median HLA-DR expression from 2666 [IQ 1547; 4991] to 12,451 [IQ 4166; 19,707], while the absolute number of lymphocyte subpopulations were not affected, except for the decrease number of NK cells 94.5 [23; 136] to 32.5 [13; 90.8] (0.0625)]. Plasma levels of IL-6 464 [201\u2013770] to 108 (89\u2013140) ng\/mL (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04) and IL-10 from IL-10 from 29 [12\u201359] to 9 [1\u201315] pg\/mL decreased significantly. Three patients who received IFN\u03b3 early after ICU admission (&lt;4\u2009days) died. The other patients had a rapid clinical improvement assessed by the SOFA score and bacterial cultures that were repeatedly positive became negative. The 2 pediatric cases improved rapidly, but 1 died for hemorrhagic complication.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Guided by clinical and immunological monitoring, adjunctive immunotherapy with IFN\u03b3 appears well-tolerated in our cases and improves immune host defense in sepsis induced immuno suppression. Randomized clinical studies to assess its potential clinical benefit are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-019-4526-x","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T11:03:18Z","timestamp":1572951798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":135,"title":["Multicentric experience with interferon gamma therapy in sepsis induced immunosuppression. A case series"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5242-6543","authenticated-orcid":false,"given":"Didier","family":"Payen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Faivre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Miatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenneke","family":"Leentjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caren","family":"Brumpt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Tissi\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Dupuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pickkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Claire","family":"Lukaszewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,5]]},"reference":[{"issue":"3","key":"4526_CR1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S1473-3099(13)70001-X","volume":"13","author":"RS Hotchkiss","year":"2013","unstructured":"Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13(3):260\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"4526_CR2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nri3552","volume":"13","author":"RS Hotchkiss","year":"2013","unstructured":"Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol. 2013;13(12):862\u201374.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"4526_CR3","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1007\/s00134-015-4045-1","volume":"41","author":"A Gouel-Cheron","year":"2015","unstructured":"Gouel-Cheron A, Allaouchiche B, Floccard B, Rimmele T, Monneret G. Early daily mHLA-DR monitoring predicts forthcoming sepsis in severe trauma patients. Intensive Care Med. 2015;41(12):2229\u201330.","journal-title":"Intensive Care Med"},{"issue":"1","key":"4526_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/SHK.0000000000000561","volume":"46","author":"F Venet","year":"2016","unstructured":"Venet F, Cour M, Demaret J, Monneret G, Argaud L. Decreased monocyte HLA-DR expression in patients after non-Shockable out-of-hospital cardiac arrest. Shock. 2016;46(1):33\u20136.","journal-title":"Shock"},{"issue":"8","key":"4526_CR5","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/bjs.1800840832","volume":"84","author":"A Klava","year":"1997","unstructured":"Klava A, Windsor A, Boylston AW, Reynolds JV, Ramsden CW, Guillou PJ. Monocyte activation after open and laparoscopic surgery. Br J Surg. 1997;84(8):1152\u20136.","journal-title":"Br J Surg"},{"issue":"10","key":"4526_CR6","first-page":"2746","volume":"37","author":"AC Lukaszewicz","year":"2009","unstructured":"Lukaszewicz AC, Grienay M, Resche-Rigon M, Pirracchio R, Faivre V, Boval B, Payen D. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction. Crit Care Med. 2009;37(10):2746\u201352.","journal-title":"Crit Care Med"},{"issue":"23","key":"4526_CR7","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1001\/jama.2011.1829","volume":"306","author":"JS Boomer","year":"2011","unstructured":"Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD 2nd, Kreisel D, Krupnick AS, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594\u2013605.","journal-title":"JAMA"},{"issue":"12","key":"4526_CR8","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1373\/clinchem.2005.052639","volume":"51","author":"WD Docke","year":"2005","unstructured":"Docke WD, Hoflich C, Davis KA, Rottgers K, Meisel C, Kiefer P, Weber SU, Hedwig-Geissing M, Kreuzfelder E, Tschentscher P, et al. Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem. 2005;51(12):2341\u20137.","journal-title":"Clin Chem"},{"issue":"6","key":"4526_CR9","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nm0697-678","volume":"3","author":"WD Docke","year":"1997","unstructured":"Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med. 1997;3(6):678\u201381.","journal-title":"Nat Med"},{"issue":"4","key":"4526_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.coi.2013.05.006","volume":"25","author":"F Venet","year":"2013","unstructured":"Venet F, Lukaszewicz AC, Payen D, Hotchkiss R, Monneret G. Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. Curr Opin Immunol. 2013;25(4):477\u201383.","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"4526_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/cc9184","volume":"14","author":"G Monneret","year":"2010","unstructured":"Monneret G, Venet F, Meisel C, Schefold JC. Assessment of monocytic HLA-DR expression in ICU patients: analytical issues for multicentric flow cytometry studies. Crit Care. 2010;14(4):432.","journal-title":"Crit Care"},{"issue":"4","key":"4526_CR12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1164\/rccm.201701-0253ED","volume":"196","author":"P Pickkers","year":"2017","unstructured":"Pickkers P. Simultaneously mounted pro- and anti-inflammatory host response relates to the development of secondary infections in patients with Sepsis. Am J Respir Crit Care Med. 2017;196(4):406\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"4526_CR13","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1164\/rccm.200903-0363OC","volume":"180","author":"C Meisel","year":"2009","unstructured":"Meisel C, Schefold JC, Pschowski R, Baumann T, Hetzger K, Gregor J, Weber-Carstens S, Hasper D, Keh D, Zuckermann H, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009;180(7):640\u20138.","journal-title":"Am J Respir Crit Care Med"},{"key":"4526_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1172\/jci.insight.98960","volume":"3","author":"B Francois","year":"2018","unstructured":"Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J, Monneret G, Rimmele T, Blood T, Morre M, et al. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018;3:5.","journal-title":"JCI Insight"},{"issue":"5","key":"4526_CR15","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/CCM.0000000000003685","volume":"47","author":"R Hotchkiss","year":"2019","unstructured":"Hotchkiss R, Olston E, Yende S, Angus D, Moldawer L, Crouser E, Martin G, Coopersmith C, Brakenridge S, Mayr F, et al. Immune checkpoint inhibition in Sepsis: a phase 1b randomized, placebo-controlled, single ascending dose study of Antiprogrammed cell death-ligand 1 antibody (BMS-936559). Crit Care Med. 2019;47(5):632\u201342.","journal-title":"Crit Care Med"},{"key":"4526_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/1471-2334-14-166","volume":"14","author":"CE Delsing","year":"2014","unstructured":"Delsing CE, Gresnigt MS, Leentjens J, Preijers F, Frager FA, Kox M, Monneret G, Venet F, Bleeker-Rovers CP, van de Veerdonk FL, et al. Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect Dis. 2014;14:166.","journal-title":"BMC Infect Dis"},{"key":"4526_CR17","doi-asserted-by":"crossref","unstructured":"A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. N Engl J Med 1991, 324(8):509\u2013516.","DOI":"10.1056\/NEJM199102213240801"},{"issue":"9","key":"4526_CR18","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1164\/rccm.201204-0645OC","volume":"186","author":"J Leentjens","year":"2012","unstructured":"Leentjens J, Kox M, Koch RM, Preijers F, Joosten LA, van der Hoeven JG, Netea MG, Pickkers P. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. Am J Respir Crit Care Med. 2012;186(9):838\u201345.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"4526_CR19","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00134-015-3751-z","volume":"41","author":"DM Payen","year":"2015","unstructured":"Payen DM, Guilhot J, Launey Y, Lukaszewicz AC, Kaaki M, Veber B, Pottecher J, Joannes-Boyau O, Martin-Lefevre L, Jabaudon M, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 2015;41(6):975\u201384.","journal-title":"Intensive Care Med"},{"issue":"1","key":"4526_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd.2017.162","volume":"17","author":"SHE Kaufmann","year":"2018","unstructured":"Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov. 2018;17(1):35\u201356.","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"4526_CR21","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00134-010-1962-x","volume":"36","author":"C Landelle","year":"2010","unstructured":"Landelle C, Lepape A, Voirin N, Tognet E, Venet F, Bohe J, Vanhems P, Monneret G. Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shock. Intensive Care Med. 2010;36(11):1859\u201366.","journal-title":"Intensive Care Med"},{"key":"4526_CR22","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jbiotec.2016.10.022","volume":"240","author":"A Razaghi","year":"2016","unstructured":"Razaghi A, Owens L, Heimann K. Review of the recombinant human interferon gamma as an immunotherapeutic: impacts of production platforms and glycosylation. J Biotechnol. 2016;240:48\u201360.","journal-title":"J Biotechnol"},{"issue":"5","key":"4526_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/jac\/dkf206","volume":"50","author":"N Bodasing","year":"2002","unstructured":"Bodasing N, Seaton RA, Shankland GS, Pithie A. Gamma-interferon treatment for resistant oropharyngeal candidiasis in an HIV-positive patient. J Antimicrob Chemother. 2002;50(5):765\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"4526_CR24","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/QAD.0b013e3283536a93","volume":"26","author":"JN Jarvis","year":"2012","unstructured":"Jarvis JN, Meintjes G, Rebe K, Williams GN, Bicanic T, Williams A, Schutz C, Bekker LG, Wood R, Harrison TS. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS. 2012;26(9):1105\u201313.","journal-title":"AIDS"},{"issue":"9","key":"4526_CR25","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1089\/088922201750251981","volume":"17","author":"LA Riddell","year":"2001","unstructured":"Riddell LA, Pinching AJ, Hill S, Ng TT, Arbe E, Lapham GP, Ash S, Hillman R, Tchamouroff S, Denning DW, et al. A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. AIDS Res Hum Retrovir. 2001;17(9):789\u201397.","journal-title":"AIDS Res Hum Retrovir"},{"issue":"1","key":"4526_CR26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/cncr.21142","volume":"104","author":"MC Dignani","year":"2005","unstructured":"Dignani MC, Rex JH, Chan KW, Dow G, de Magalhaes-Silverman M, Maddox A, Walsh T, Anaissie E. Immunomodulation with interferon-gamma and colony-stimulating factors for refractory fungal infections in patients with leukemia. Cancer. 2005;104(1):199\u2013204.","journal-title":"Cancer"},{"issue":"1","key":"4526_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1086\/517077","volume":"26","author":"CH Poynton","year":"1998","unstructured":"Poynton CH, Barnes RA, Rees J. Interferon gamma and granulocyte-macrophage colony-stimulating factor for the treatment of hepatosplenic candidosis in patients with acute leukemia. Clin Infect Dis. 1998;26(1):239\u201340.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"4526_CR28","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/j.1600-6143.2010.03094.x","volume":"10","author":"D Armstrong-James","year":"2010","unstructured":"Armstrong-James D, Teo IA, Shrivastava S, Petrou MA, Taube D, Dorling A, Shaunak S. Exogenous interferon-gamma immunotherapy for invasive fungal infections in kidney transplant patients. Am J Transplant. 2010;10(8):1796\u2013803.","journal-title":"Am J Transplant"},{"issue":"7","key":"4526_CR29","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1097\/00003246-200207000-00015","volume":"30","author":"G Nakos","year":"2002","unstructured":"Nakos G, Malamou-Mitsi VD, Lachana A, Karassavoglou A, Kitsiouli E, Agnandi N, Lekka ME. Immunoparalysis in patients with severe trauma and the effect of inhaled interferon-gamma. Crit Care Med. 2002;30(7):1488\u201394.","journal-title":"Crit Care Med"},{"key":"4526_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijid.2017.03.013","volume":"59","author":"J Leentjens","year":"2017","unstructured":"Leentjens J, Gresnigt MS, van de Veerdonk FL, Kox M, Kullberg BJ, Pickkers P, Brouwer AE, Netea MG. Adjuvant interferon-gamma immunotherapy in a patient with progressive cerebral Nocardia abscesses. Int J Infect Dis. 2017;59:25\u20138.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"4526_CR31","doi-asserted-by":"publisher","first-page":"e32863","DOI":"10.1371\/journal.pone.0032863","volume":"7","author":"P Tissieres","year":"2012","unstructured":"Tissieres P, Ochoda A, Dunn-Siegrist I, Drifte G, Morales M, Pfister R, Berner M, Pugin J. Innate immune deficiency of extremely premature neonates can be reversed by interferon-gamma. PLoS One. 2012;7(3):e32863.","journal-title":"PLoS One"},{"issue":"2","key":"4526_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ccm.2016.01.003","volume":"37","author":"TE Sweeney","year":"2016","unstructured":"Sweeney TE, Wong HR. Risk stratification and prognosis in Sepsis: what have we learned from microarrays? Clin Chest Med. 2016;37(2):209\u201318.","journal-title":"Clin Chest Med"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4526-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-4526-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-4526-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T19:06:05Z","timestamp":1604430365000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-4526-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,5]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4526"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-4526-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,5]]},"assertion":[{"value":"8 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The cohort 1 was collected from the data of the large project on \u201cSevere Sepsis and inflammation monitoring\u201d approved by Cochin Hospital Ethics Committee (# CCPPRB 2061), Assistance Publique-H\u00f4pitaux de Paris. For each patient of the cohort 1, a clear explanation of the justification to use IFN\u03b3 was given, based on the literature and on the experience of the research clinical team. According to the French law and with the agreement of the Institutional Pharmacy Board, IFN\u03b3 was proposed as a compassionate treatment with clear explanation given to the patient\u2019s next of kin about the potential risks and benefits.For each pediatric case, IFN\u03b3 administration was a multidisciplinary decision between intensivists, surgeons and hepatologists, which was proposed to the parents as a compassionate treatment. The compassionate therapy by IFN\u03b3 was validated by institutional pharmacist after a review of the literature. Decisional process was notified in the hospitalization records and synthesis note with signature on the medical charts.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the parent of the patients for publication of these Case Report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors have any competing interests regarding this study. In this study, the support for the immunological assessments was covered by payment of additional immune tests in the global cost for care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"931"}}